3Nguyen MH,Yu CY.Voriconazole against fiuconazole-susceptible and resistant candida isolates:in uitro efficacy compared with that of itraconazole and ketoconazole[J].J Antimicrob Chemother,1998,42(2):253-256.
4Barchiesi F,Arzeni D,Fothergill AW,et al.In uitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens[J].Antimicrob Agents Chemother,2000,44(1):226-229.
5Nomeir AA,Kumari P,Hilbert MJ,et al.pharmacokinetics of SCH 56592,a new azole broad-spectrum antifungal agent,in mice,rats,rabbits,dogs,and eynomolgus monkeys[J].Antiuficrob Agents Chemother,2000,44(3):727-731.
6Moore CB,Walls CM,Denning DW.In uitm activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B[J].Antimicrob Agents Chemother,2000,44(2):441-443.
5中岛茂.作用机序から眺めた抗真菌药の现状と展望[J].Jpn J Med Mycol,1999,40(3):119-121.
6Yotsuji A,Shimizu K,Araki H,et al.T-8581,a new orally and parenterally active triazole antifungal agent:in vitro and in vivo evaluations[J].Antimicrob Agents Chemother,1997,41(1)∶30-34.
7Ji HT,Zhang WW,Zhou YJ,et al.A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals[J].J Med Chem,2000,43(13)∶2493-2505.
8Cornely OA,Schmitz K,Aisenbrey S.The first echinocandin:Caspofungin[J].Mycoses,2002,45(Suppl 3)∶S56-S59.
9Arikan S,Rex JH.New agents for the treament of systemic fungal infections-current status[J].Expert Opin Emerging Drugs,2002,7(1)∶3-6.
10Kauffmann CA.Carver PL.Antifungal agents in the 1990s.Current status and future developments[J].Drugs,1997,53(4)∶539-542.
